Although EGLF7 expression was not regulated by ibrutinib, there was a strong positive correlation between the expression of miR‐126 and EGFL7 in CLL patient samples before and after ibrutinib therapy (P < 0.001, Fig. 2B). The gene discussed is EGFL7; the disease is B-cell chronic lymphocytic leukemia.